Breakthrough Fusarium spp fungemia during caspofungin therapy in an ABO-incompatible orthotopic liver transplant patient.
Tascini
C
C
Urbani
L
L
Doria
R
R
Catalano
G
G
Leonildi
A
A
Filipponi
F
F
Menichetti
F
F
D000017:ABO Blood-Group System; D000666:Amphotericin B / Q000008:administration & dosage; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy / Q000276:immunology; D000077336:Caspofungin; D004359:Drug Therapy, Combination; D054714:Echinocandins / Q000627:therapeutic use*; D005260:Female; D016469:Fungemia / Q000188:drug therapy* / Q000276:immunology*; D005670:Fusarium; D006084:Graft Rejection / Q000517:prevention & control; D006648:Histocompatibility; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D055666:Lipopeptides; D016031:Liver Transplantation / Q000009:adverse effects* / Q000276:immunology; D000077731:Meropenem; D008875:Middle Aged; D017334:Teicoplanin / Q000008:administration & dosage; D013845:Thienamycins / Q000008:administration & dosage
D000017:ABO Blood-Group System; D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D054714:Echinocandins; D007166:Immunosuppressive Agents; D055666:Lipopeptides; D013845:Thienamycins; C068538:liposomal amphotericin B; D017334:Teicoplanin; D000666:Amphotericin B; D000077336:Caspofungin; D000077731:Meropenem